|
| | Dabigatran | Rivaroxaban | Apixaban |
|
| Prothrombin Time (PT) | Time prolonged + (relative to reagent sensitivity) | Time prolonged + to +++ (relative to reagent sensitivity) | Time non-prolonged or prolonged + (relative to reagent sensitivity) |
|
| Activated Partial Thromboplastin Time (aPTT) | Time prolonged + to +++ (relative to reagent sensitivity) | Time prolonged + (relative to reagent sensitivity) | Time prolonged + (relative to reagent sensitivity) |
|
| PT-based coagulation factors measurement (II, VII, IX, X) | Slightly decreased (depending on the reagent) | Slightly decreased (depending on the reagent) | Slightly decreased (depending on the reagent) |
|
| APTT-based coagulation factors measurement (VIII, IX, XI) | Slightly decreased (depending on the reagent) | Slightly decreased (depending on the reagent) | Slightly decreased (depending on the reagent) |
|
| Fibrinogen | No influence or slightly decrease (depending on the reagent) | No influence | No influence |
|
| Thrombin Time | Time prolonged +++++ | No influence | No influence |
|
| Anti-Xa based antithrombin measurement | No influence | Increased: 10% per 100 ng/mL | Increased: 10% per 100 ng/mL |
|
| Anti-IIa based antithrombin measurement | Increased: 5–10% per 100 ng/mL | No influence | No influence |
|
